DiaMedica Announces Issuance of Stock Options
November 04 2010 - 1:35PM
Marketwired
DiaMedica (TSX VENTURE: DMA) today wishes to announce the issuance
of stock options to the Company's management, directors, staff and
consultants. DiaMedica has issued 1,428,500 stock options to the
Company's management, directors, staff and consultants at an
exercise price of $0.68 per share. These options will expire no
later than November 4, 2015 subject to applicable vesting
provisions. These options were awarded in accordance with the
Company's stock option plan.
About DiaMedica
DiaMedica is a biopharmaceutical company focused on developing
novel treatments for type 1 diabetes, type 2 diabetes and other
disorders. DiaMedica has completed two successful proof-of-concept
Phase II studies with DM-71 and DM-99, which demonstrated human
efficacy in lowering blood glucose levels in patients with type 2
diabetes.
DiaMedica's lead product DM-199 is a novel recombinant next
generation form of DM-99, which has shown the potential to increase
insulin sensitivity, reduce the autoimmune attack and trigger
proliferation of pancreatic beta cells, neural stem cells and bone
marrow cells. DiaMedica is listed on the TSX Venture Exchange under
the trading symbol "DMA". For further information please visit
www.diamedica.com.
Caution Regarding Forward-Looking Information
Certain statements contained in this press release constitute
forward-looking information within the meaning of applicable
Canadian provincial securities legislation (collectively, the
"forward-looking statements"). These forward-looking statements
relate to, among other things, DiaMedica's objectives, goals,
targets, strategies, intentions, plans, beliefs, estimates and
outlook, and can, in some cases, be identified by the use of words
such as "believe," "anticipate," "expect," "intend," "plan,"
"will," "may" and other similar expressions. In addition, any
statements that refer to expectations, projections or other
characterizations of future events or circumstances are
forward-looking statements. Specifically, this press release
contains forward-looking statements regarding matters such as, but
not limited to, the anticipated use of proceeds from the Offering,
management's assessment of DiaMedica's future plans, information
with respect to the advancement of DiaMedica's research and
development programs, and DiaMedica's other estimates and
expectations.
These statements reflect management's current beliefs and are
based on information currently available to management. Certain
material factors or assumptions are applied in making
forward-looking statements, and actual results may differ
materially from those expressed or implied in such statements.
Important factors that could cause actual results to differ
materially from these expectations include, among other things:
uncertainties and risks related to our research and development
programs, the availability of additional financing, risks and
uncertainties relating to the anticipated use of proceeds, changes
in debt and equity markets, uncertainties related to clinical
trials and product development, rapid technological change,
uncertainties related to forecasts, competition, potential product
liability, additional financing requirements and access to capital,
unproven markets, the cost and supply of raw materials, management
of growth, effects of insurers' willingness to pay for products,
risks related to regulatory matters and risks related to
intellectual property matters. Additional information about these
factors and about the material factors or assumptions underlying
such forward-looking statements may be found in the body of this
news release, as well as under the heading "Risk Factors" contained
in DiaMedica's 2009 annual information form. DiaMedica cautions
that the foregoing list of important factors that may affect future
results is not exhaustive. When relying on DiaMedica's
forward-looking statements to make decisions with respect to
DiaMedica, investors and others should carefully consider the
foregoing factors and other uncertainties and potential events.
Such forward-looking statements are based on a number of estimates
and assumptions, which may prove to be incorrect, including, but
not limited to, assumptions regarding the availability of
additional financing for research and development companies, and
general business and economic conditions. These risks and
uncertainties should be considered carefully and investors and
others should not place undue reliance on the forward-looking
statements. Although the forward-looking statements contained in
this press release are based upon what management believes to be
reasonable assumptions, DiaMedica cannot provide assurance that
actual results will be consistent with these forward-looking
statements. DiaMedica undertakes no obligation to update or revise
any forward-looking statement. Additional risk factors, factors
which could cause actual results to differ materially from
expectations, and assumptions relating specifically to our
acquisition of Sanomune may be found in our press releases dated
February 18, 2010 and April 20, 2010.
Contacts: DiaMedica Inc. Rick Pauls 204.477.7590 204.453.3745
(FAX) rpauls@diamedica.com
DiaMedica Inc. (TSXV:DMA)
Historical Stock Chart
From Jun 2024 to Jul 2024
DiaMedica Inc. (TSXV:DMA)
Historical Stock Chart
From Jul 2023 to Jul 2024